Fundraising FoxBrickbio
Boston, US · Founded 2019 · Delaware corporation
Find your way into Brickbio
Sign up to see every warm intro you have to Brickbio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Brickbio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BrickBio develops protein and antibody-drug conjugate (ADC) therapeutics using its Evolved tRNA Localization (ETRNAL) platform, which incorporates synthetic amino acid conjugation handles at specific sites in a protein backbone via mammalian expression systems. The company targets pharmaceutical and biotech applications, aiming to produce more stable and efficacious conjugated biologics, including multi-payload conjugates.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2019
▶$5MraisedNov 2019 · 2 investors · BiotechnologyRule 506(b)
▶$5MraisedNov 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott ShermanExecutive Officer, Director
- Alexander RobertsonExecutive Officer
- Elouise ManhertzExecutive Officer
- Caylin NavoExecutive Officer
- John BoyceDirector
- Cheri WalkerDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
ClickBio, Inc.ClickBio manufactures laboratory automation hardware and reagent handling equipment for life sciences research, including reagent reservoirs, fill stations, and plate adapters compatible with standard microplate formats.
ARTBIOARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.
AskBioAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Generate BiomedicinesGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
Eclipse BioEclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
Companies working in the same space as Brickbio.
Frequently asked questions
- What does Brickbio do?
- BrickBio develops protein and antibody-drug conjugate (ADC) therapeutics using its Evolved tRNA Localization (ETRNAL) platform, which incorporates synthetic amino acid conjugation handles at specific sites in a protein backbone via mammalian expression systems. The company targets pharmaceutical and biotech applications, aiming to produce more stable and efficacious conjugated biologics, including multi-payload conjugates.
- How much funding has Brickbio raised?
- Brickbio has disclosed $5M raised across 1 round.
- Where is Brickbio headquartered?
- Brickbio is headquartered in Boston, US.